Alvotech Appoints Patrik Ling as VP of Investor Relations for Scandinavia

Alvotech, a global leader in biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia. Ling brings over 25 years of experience in the life-science industry and will be based in Stockholm. The appointment aims to expand Alvotech's Scandinavian shareholder base and strengthen its R&D operations in Sweden.

Reykjavik, Iceland (August 20, 2025) — Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia. Ling, with over 25 years of experience in the life-science industry, will be based in Stockholm. This appointment aims to expand Alvotech's Scandinavian shareholder base and strengthen its R&D operations in Sweden [1].

Patrik Ling has a diverse background, having initially worked in marketing and sales of pharmaceuticals before transitioning to the financial sector. Most recently, he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech [2]. His expertise in both pharma and finance positions him to be a valuable asset to Alvotech's investor relations team.

"Alvotech is thrilled to have Patrik on board," said Róbert Wessman, chairman and CEO of Alvotech. "His extensive experience and deep understanding of the life science industry in Scandinavia will be instrumental in broadening our shareholder base and solidifying our position as a leading life science company in the Nordics."

Ling expressed his enthusiasm for the role, stating, "This is an exciting time to join Alvotech, given its expanding portfolio of products and the new R&D operations in Sweden. Biosimilars play a crucial role in meeting the growing demand for high-quality biologics and controlling healthcare costs. I look forward to engaging with Scandinavian investors and helping them understand Alvotech's strengths and value proposition."

About Alvotech
Alvotech is a biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The company seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services. Currently, two biosimilars to Humira® (adalimumab) and Stelara® (ustekinumab) are approved and marketed in multiple global markets. Alvotech has a robust pipeline of nine disclosed biosimilar candidates aimed at treating various conditions, including autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [1].

Alvotech has formed strategic commercial partnerships to provide global reach and leverage local expertise. These partnerships include collaborations with Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd., and others [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/20/3136263/0/en/Alvotech-appoints-Patrik-Ling-as-VP-of-Investor-Relations-Scandinavia.html
[2] https://www.biospace.com/press-releases/alvotech-appoints-patrik-ling-as-vp-of-investor-relations-scandinavia